Cornerstone Pharmaceuticals (02616) issued a voluntary announcement stating that Cornerstone Pharmaceuticals continues to operate normally, and there have been no major changes in business operations or financial conditions, and the company's business is basically proceeding according to plan.
The Zhitong Finance App learned that on March 4, Cornerstone Pharmaceutical (02616) issued a voluntary announcement stating that Cornerstone Pharmaceuticals continues to operate normally, that there are no major changes in business operations or financial conditions, and that the company's business is basically proceeding according to plan.
Cornerstone Pharmaceuticals focuses on research, development and commercialization of innovative tumor immunotherapy and precision therapy drugs. In December of last year, Cornerstone Pharmaceuticals announced various business developments, including phased data for ROR1 ADC (CS5001), overseas progress of Zegemei (sugarimab), and strategic cooperation with Sansheng Pharmaceutical and Alice. In addition, Cornerstone Pharmaceuticals' many late-stage drug candidates are in critical clinical trials or registration stages.
Industry insiders have analyzed that since the end of last year, a series of actions by Cornerstone Pharmaceuticals are conducive to the continuous development and expansion of its own advantages, focusing its strategy and management on the R&D stage, and promoting the development and marketing of more differentiated innovative drugs. There were changes in Cornerstone Pharmaceuticals' market today, or due to Cornerstone Pharmaceutical-B being transferred out of Hong Kong Stock Connect.
According to the Cornerstone Pharmaceutical announcement, more information on the company's business operations and financial situation will be provided in the company's annual results announcement scheduled to be issued at the end of March and the investor briefing session the company plans to hold after the announcement of the annual results.